Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017752649> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2017752649 abstract "Melanoma immunotherapy based on immune checkpoint blockade, by targeting of CTLA-4 or PD-1, has markedly improved the treatment of advanced disease, as shown by several recent trials. Monotherapy with CTLA-4-specific antibody (Ipilimumab) prolongs overall survival, while PD-1-specific antibodies (Nivolumab and Lambrolizumab) induce durable tumor regression in a large fraction of patients. Moreover, a recent trial based on combination checkpoint blockade (Ipilimumab plus Nivolumab) has shown an objective response rate of 53%, with tumor reduction of 80% in responding patients, without escalation of toxic effects. In spite of these highly relevant results, clinical benefit by immunotherapy targeting CTLA-4 or PD-1 remains limited to a fraction of patients. This points to the existence of immune escape mechanisms, which, in some tumors, may prevent effective elimination of neoplastic cells, in spite of the reactivated T cell immunity. This hypothesis was tested in a melanoma patient, treated with Ipilimumab, and that we recently reported (J. Clin. Oncol. 29:e783-8, 2011) to have a strong T cell infiltrate and evidence of T cell maturation/activation only in a regressing right adrenal metastasis, but not in the progressing controlateral lesion. To this end, we carried out DASL whole genome gene expression analysis and extensive immunohistochemistry (IHC) on paraffin-embedded neoplastic tissues. The results indicated that, in comparison to the progressing metastasis, the regressing lesion had a distinct gene expression profile characterized by enhanced expression of several genes involved in T cell differentiation to cytolytic effector stage. Most importantly, the regressing lesion retained expression of HLA molecules on neoplastic cells. In contrast, the progressing lesion showed almost complete loss of HLA class I and Class II molecules by the tumor, as documented by IHC. Taken together, these results suggest that lack/loss of expression of HLA molecules, by tumor cells, may represent a highly effective tumor resistance mechanism to immune checkpoint blockade. Moreover, pre-therapy IHC on tumor samples may allow to test whether HLA antigen expression/loss is a predictive marker for response/resistance to therapy targeting CTLA-4 or PD-1.Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A89.Citation Format: Andrea Anichini, Filippo G. de Braud, Roberta Montarini, Ilaria Bersani, Gabrina Tragni, Loris de Cecco, Silvana Canevari, Lorenza Di Guardo, Lorenzo Pilla, Michele Del Vecchio. Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A89." @default.
- W2017752649 created "2016-06-24" @default.
- W2017752649 creator A5000391768 @default.
- W2017752649 creator A5001956192 @default.
- W2017752649 creator A5017161374 @default.
- W2017752649 creator A5018481533 @default.
- W2017752649 creator A5020982369 @default.
- W2017752649 creator A5032506137 @default.
- W2017752649 creator A5058856359 @default.
- W2017752649 creator A5061225830 @default.
- W2017752649 creator A5071691136 @default.
- W2017752649 date "2013-11-01" @default.
- W2017752649 modified "2023-09-25" @default.
- W2017752649 title "Abstract A89: Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy." @default.
- W2017752649 doi "https://doi.org/10.1158/1535-7163.targ-13-a89" @default.
- W2017752649 hasPublicationYear "2013" @default.
- W2017752649 type Work @default.
- W2017752649 sameAs 2017752649 @default.
- W2017752649 citedByCount "1" @default.
- W2017752649 countsByYear W20177526492015 @default.
- W2017752649 crossrefType "proceedings-article" @default.
- W2017752649 hasAuthorship W2017752649A5000391768 @default.
- W2017752649 hasAuthorship W2017752649A5001956192 @default.
- W2017752649 hasAuthorship W2017752649A5017161374 @default.
- W2017752649 hasAuthorship W2017752649A5018481533 @default.
- W2017752649 hasAuthorship W2017752649A5020982369 @default.
- W2017752649 hasAuthorship W2017752649A5032506137 @default.
- W2017752649 hasAuthorship W2017752649A5058856359 @default.
- W2017752649 hasAuthorship W2017752649A5061225830 @default.
- W2017752649 hasAuthorship W2017752649A5071691136 @default.
- W2017752649 hasConcept C121608353 @default.
- W2017752649 hasConcept C126322002 @default.
- W2017752649 hasConcept C159654299 @default.
- W2017752649 hasConcept C170493617 @default.
- W2017752649 hasConcept C203014093 @default.
- W2017752649 hasConcept C21705690 @default.
- W2017752649 hasConcept C2776090121 @default.
- W2017752649 hasConcept C2777658100 @default.
- W2017752649 hasConcept C2777701055 @default.
- W2017752649 hasConcept C2778468042 @default.
- W2017752649 hasConcept C2780030458 @default.
- W2017752649 hasConcept C2780851360 @default.
- W2017752649 hasConcept C2781433595 @default.
- W2017752649 hasConcept C502942594 @default.
- W2017752649 hasConcept C71924100 @default.
- W2017752649 hasConcept C8891405 @default.
- W2017752649 hasConceptScore W2017752649C121608353 @default.
- W2017752649 hasConceptScore W2017752649C126322002 @default.
- W2017752649 hasConceptScore W2017752649C159654299 @default.
- W2017752649 hasConceptScore W2017752649C170493617 @default.
- W2017752649 hasConceptScore W2017752649C203014093 @default.
- W2017752649 hasConceptScore W2017752649C21705690 @default.
- W2017752649 hasConceptScore W2017752649C2776090121 @default.
- W2017752649 hasConceptScore W2017752649C2777658100 @default.
- W2017752649 hasConceptScore W2017752649C2777701055 @default.
- W2017752649 hasConceptScore W2017752649C2778468042 @default.
- W2017752649 hasConceptScore W2017752649C2780030458 @default.
- W2017752649 hasConceptScore W2017752649C2780851360 @default.
- W2017752649 hasConceptScore W2017752649C2781433595 @default.
- W2017752649 hasConceptScore W2017752649C502942594 @default.
- W2017752649 hasConceptScore W2017752649C71924100 @default.
- W2017752649 hasConceptScore W2017752649C8891405 @default.
- W2017752649 hasLocation W20177526491 @default.
- W2017752649 hasOpenAccess W2017752649 @default.
- W2017752649 hasPrimaryLocation W20177526491 @default.
- W2017752649 hasRelatedWork W1968186049 @default.
- W2017752649 hasRelatedWork W2318979033 @default.
- W2017752649 hasRelatedWork W2337253567 @default.
- W2017752649 hasRelatedWork W2340296324 @default.
- W2017752649 hasRelatedWork W2400310528 @default.
- W2017752649 hasRelatedWork W2546537212 @default.
- W2017752649 hasRelatedWork W2591659465 @default.
- W2017752649 hasRelatedWork W2592409680 @default.
- W2017752649 hasRelatedWork W2734739695 @default.
- W2017752649 hasRelatedWork W2911755946 @default.
- W2017752649 hasRelatedWork W2916292904 @default.
- W2017752649 hasRelatedWork W2921402408 @default.
- W2017752649 hasRelatedWork W2935915110 @default.
- W2017752649 hasRelatedWork W2954566614 @default.
- W2017752649 hasRelatedWork W3010430375 @default.
- W2017752649 hasRelatedWork W3019679892 @default.
- W2017752649 hasRelatedWork W3034240075 @default.
- W2017752649 hasRelatedWork W3083552744 @default.
- W2017752649 hasRelatedWork W3107820270 @default.
- W2017752649 hasRelatedWork W3126504462 @default.
- W2017752649 isParatext "false" @default.
- W2017752649 isRetracted "false" @default.
- W2017752649 magId "2017752649" @default.
- W2017752649 workType "article" @default.